Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04913285 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Pierre Fabre Medicament.

Active
Registry status
Phase 1
Development phase
400
Enrollment target
20
Study locations

NCT04913285 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by Pierre Fabre Medicament. The registered enrollment target is 400 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04913285, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by Pierre Fabre Medicament.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

Conditions Studied

Non-Small Cell Lung Cancer Melanoma Solid Tumor, Adult

Interventions

  • DRUG KIN-2787
  • DRUG KIN-2787 and binimetinib

Study Locations (20)

California

  • The Angeles Clinic - Los Angeles
  • UCLA - Los Angeles
  • University of California San Diego, Moores Cancer Center - San Diego
  • University of California San Francisco - San Francisco
  • Stanford Cancer Center - Stanford

Florida

  • Mayo Clinic - Florida - Jacksonville
  • Sarah Cannon Research Institute - Florida Cancer Specialists - Orlando

New Jersey

  • Atlantic Health - Morristown
  • Rutgers Cancer Institute of New Jersey - New Brunswick

New York

  • NYU Langone - New York
  • Memorial Sloan Kettering Cancer Center - New York

New South Wales

  • Calvary Mater Hospital Newcastle - Waratah
  • Melanoma Institute Australia - Wollstonecraft

Colorado

  • Sarah Cannon Research Institute Denver - Denver

Minnesota

  • Mayo Clinic - Rochester - Rochester

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2021-08-04
Est. Completion 2029-03-30
Phase Phase 1

Sponsor

Pierre Fabre Medicament

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04913285

The ClinicalTrials.gov registry entry for NCT04913285 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (39% lower). The listed sponsor is Pierre Fabre Medicament, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which KIN-2787 is the first listed.

NCT04913285 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, New Jersey.

Frequently Asked Questions

What is clinical trial NCT04913285 about?

NCT04913285 is a clinical study titled "A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

What is the current status of trial NCT04913285?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 400 participants. The study started on 2021-08-04. Estimated completion is 2029-03-30.

What conditions does trial NCT04913285 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Solid Tumor, Adult.

What interventions are being tested in trial NCT04913285?

The interventions under investigation include: KIN-2787 (DRUG), KIN-2787 and binimetinib (DRUG).

Who is sponsoring clinical trial NCT04913285?

This trial is sponsored by Pierre Fabre Medicament, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04913285 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.